HOWL stock icon

Werewolf Therapeutics
HOWL

$2.02
0.49%

Market Cap: $88.3M

 

About: Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

Employees: 45

0
Funds holding %
of 6,686 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

4,267% more call options, than puts

Call options by funds: $131K | Put options by funds: $3K

75% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 12

71% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 14

15% more funds holding

Funds holding: 61 [Q1] → 70 (+9) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

1.33% less ownership

Funds ownership: 75.51% [Q1] → 74.17% (-1.33%) [Q2]

62% less capital invested

Capital invested by funds: $209M [Q1] → $78.7M (-$130M) [Q2]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$12
494%
upside
Avg. target
$14
593%
upside
High target
$15
643%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Andres Maldonado
42% 1-year accuracy
16 / 38 met price target
643%upside
$15
Buy
Reiterated
2 Jul 2024
JMP Securities
Reni Benjamin
44% 1-year accuracy
14 / 32 met price target
494%upside
$12
Market Outperform
Reiterated
26 Jun 2024
HC Wainwright & Co.
Andres Maldonado
42% 1-year accuracy
16 / 38 met price target
643%upside
$15
Buy
Reiterated
26 Jun 2024

Financial journalist opinion